Czechia· CZ-0029033

EMSELEX

A darifenacin product containing darifenacin hydrobromide, registered in Czechia by pharmaand GmbH, Vienna. The same ATC class is registered in 15 of our 19 countries.

ATC G04BD10

Checked against SÚKL (Czech Republic) on

Informational only — not a medical device.

SOURCE REGISTER · CZSÚKL (Czech Republic)normalisedEMSELEXATCG04BD10REGISTER NO.CZ-0029033PACKS LISTED0CHECKEDSeptember 28, 2026

Where it is registered

Darifenacin is registered in 15 of 19 countries.

Countries holding a registration under ATC G04BD10 (darifenacin), each read from that country’s own register.

  • This record: Czechia, from SÚKL (Czech Republic)
  • 9 of them publish a price we can compare per daily dose

Darifenacin · ATC G04BD10

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of darifenacin costs, country by country.

Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Darifenacin · price per daily dose (7.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.84
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

SÚKL (Czech Republic)
Active substance
DARIFENACIN HYDROBROMIDE
Manufacturer
pharmaand GmbH, Vienna
Country
Czechia (CZ)
ATC code
G04BD10
ATC class
Darifenacin
Defined daily dose
7.5 mg, O
Reimbursed
Not published by this register
Source register
SÚKL (Czech Republic)
Last checked
September 28, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

246 interactions on record for darifenacin.

Graded by severity as the source publishes them — 13 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Darifenacin · interactions on record

246 records

  • 13 severe
  • 155 moderate
  • 1 minor
  • 49 info

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • EliglustatA16AX10severe
  • Potassium chlorideB05XA01severe

28 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Darifenacin in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All darifenacin products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Germany · Darifenacin Aristo
  • Spain · Darifenacina Aristo
  • United Kingdom (Northern Ireland) · Darifenacin Aristo
  • Iceland · Emselex
  • Liechtenstein · Emselex
  • Netherlands · Darifenacine Aristo
  • Norway · Emselex
  • Portugal · Darifenacina Aristo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/19e5a20f-3fee-45ce-b45e-ff7ffd8af4c4
GET /v1/drugs/19e5a20f-3fee-45ce-b45e-ff7ffd8af4c4?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "TBL PRO",
  "source": "sukl",
  "strength": "15MG",
  "pack_size": "140(14X10) II",
  "substance": "DARIFENACIN HYDROBROMIDE",
  "cz_kod_sukl": "0029033",
  "product_type": "CH",
  "substance_codes": "14450",
  "registration_state": "R",
  "registration_number": "EU/1/04/294/028"
}

See everything about darifenacin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.